Insulin is becoming important for us
Over the next five years, what would you see as challenges to get to your target of $1 billion in annual revenue?
Basically we are much more confident of delivering on a $1-billion topline than what we would have been a few years ago because there were a lot of regulatory uncertainties. We donít have a very clear perspective of what the regulators will finally approve in many of the very regulated markets.
But having said that, we are now seeing that rest-of-the-world markets or emerging markets are very lucrative, these are the fastest growing markets. Everyone is focussing on the US and Europe, but they are the slowest growing markets.
Insulin is becoming a very important product for us. One thing we have seen is that after parting ways with Pfizer, our insulin business has surged. Thatís because we were actually not able to grow those businesses because Pfizer was not really pursuing those markets. Once Pfizer went, it gave us the option to pursue those markets and we are suddenly seeing a huge growth in insulins.
Basically, now we are finding that we are short of capacity. We are constrained right now by capacity, not by the market. If we had the capacity, the insulin business
Be the first to comment.